Until then, clinicians should continue evidence-based practice and keep an eye on the evolving science
Coordenador do Servio de Cardiologia e Cirurgia Cardaca da Santa Casa de Barra Mansa
MSCs with high cellular GSH levels have improved chondrogenic potential Although there was no difference in size and weight among the three groups of cells (Fig
For instance, semaglutide received FDA and EMA approval for cardiovascular risk reduction in patients with obesity in 2024, and Novo Nordisk are also targeting the use of semaglutide in patients with obesity-related heart failure and metabolic associated steatohepatitis (MASH, formerly known as fatty liver disease)
We focus on providing personalized, comprehensive weight loss solutions, not just injections
Following the 3-awardees guideline, the committee selected the current three laureates as the most deserving ones.